M. Martín Jiménez - Concepedia

Author

M. Martín Jiménez

Hospital General Universitario Gregorio Marañón

Also Known As

Estela Vega Alonso, M Martin Jimenez, M Martín Jiménez, M. Martin Jimenez, M. Martín Jiménez, MIGUEL MARTÍN JIMÉNEZ, Marina Jimenez, Maryhen Jiménez, Miguel Jiménez, Miguel Martin Jimenez

Publications

975

Citations

H-Index

Concepts

All Affiliations

Hospital General Universitario Gregorio Marañón The University of Texas MD Anderson Cancer Center Sarah Cannon Seoul National University Hospital Institute of Cancer Research

About

M. Martín Jiménez is an author at Hospital General Universitario Gregorio Marañón specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	668
2	Health Sciences	4	4	123
3	Emergency Medicine	1	1	13
4	Immunology	1	1	11
5	Neurology	1	1	13

M. Martín Jiménez

Publications

759

Citations

H-Index

Page 1

	Year	Citations
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study M. Martín Jiménez, Elgene Lim, Mariana Chávez‐MacGregor, Annals of Oncology Endocrine OncologyVs Physician ChoiceAdvanced/metastatic Breast CancerPhase IiBreast Oncology	2022	57
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model Andrés J. Muñoz Martín, Pilar Alfonso, Ana Belén Rúperez Blanco, Clinical & Translational Oncology ThrombosisPredictive ModelVenous ThrombosisPancreatic CancerMedicine	2014	50
LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial Peter A. Fasching, Daniil Stroyakovskiy, Denise A. Yardley, Annals of Oncology Breast OncologyOncologyLba13 Adjuvant RibociclibMedicineClinical Trials	2024	42
Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors Pedro León, M. Martín Jiménez, Pascual Barona, Medical and Pediatric Oncology	1998	41
162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer E.P. Hamilton, Charles L. Shapiro, Valentina Boni, Annals of Oncology Breast OncologyOpen LabelMedicinePathologyPhase Ib Trial	2022	36
Clinical guide SEOM on venous thromboembolism in cancer patients Andrés J. Muñoz Martín, Carme Font, M Navarro, Clinical & Translational Oncology	2014	29
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes Nadia Harbeck, Priya Rastogi, J. O’Shaughnessy, Annals of Oncology 5-Year Efficacy OutcomesBreast OncologyMedicineCancer ManagementPharmacology	2023	18
Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status Laura Ortega, Pilar Alfonso, Iker Aguilar Caballero, Clinical & Translational Oncology ThrombosisVenous ThrombosisCancer EpidemiologyMedicineColorectal Cancer	2020	14
Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies Javier Puente, Sara López‐Tarruella, José Á. García-Sáenz, Clinical & Translational Oncology Neuro-oncologyBreast OncologyBrain MetastasesMedicineBreast Cancer	2006	13

Page 1